The Alzheimer’s Screening and Prevention (ASAP) Act adds a new Medicare benefit category for ‘‘Alzheimer’s disease and related dementias early detection screening tests,’’ and requires Medicare payment for those tests beginning January 1, 2028. The bill defines covered tests by linking eligibility to FDA clearance, classification, or approval and enumerates a wide set of technologies—explicitly including genomic sequencing of blood or blood products and a catch-all for ‘‘equivalent’’ tests the Secretary deems comparable.
This is a narrow but consequential statutory change: it does not create clinical guidelines or payment rates, but it makes these screening technologies explicitly payable under Medicare law and directs CMS to treat them as covered items. That shifts the policy question from whether such tests may be reimbursed to how CMS manages coverage, accuracy standards, coding, and downstream clinical and budgetary impacts.
At a Glance
What It Does
The bill amends section 1861 of the Social Security Act to define a new class of Medicare-covered tests for pre-symptomatic and early-stage Alzheimer’s and related dementias, and amends the payment provision in section 1833 to include those tests in Medicare payment authority. Tests must be FDA-cleared, classified, or approved and may include a broad range of genomic and other biomarker technologies.
Who It Affects
Directly affects diagnostic test manufacturers (especially developers of blood-based genomic and protein assays), clinical laboratories, and Medicare beneficiaries eligible for screening. CMS and Medicare contractors will handle implementation, while clinicians and health systems will face new screening and follow-up pathways.
Why It Matters
By codifying Medicare coverage for these tests, the bill effectively opens a large, guaranteed payer market for blood-based dementia diagnostics and forces CMS to set coverage and payment policies. It also accelerates the clinical and fiscal implications of widespread pre-symptomatic screening without specifying clinical standards or downstream care pathways.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The ASAP Act creates a new, named Medicare benefit category for tests that detect Alzheimer’s disease and related dementias in people before or in the early stages of symptoms. The bill does two things in statute: it inserts a definition into the Social Security Act that identifies which tests qualify, and it updates Medicare’s payment statute so those defined tests are payable.
The definition limits eligibility to tests that have a specific FDA regulatory pathway—510(k) clearance, classification under 513(f)(2), or premarket approval under 515—and then lists technologies that qualify, with genomic sequencing of blood or blood products called out by name.
The definition reaches beyond a single test type by expressly including ‘‘other equivalent tests’’ and a non-exhaustive list (single-analyte tests, cell-free nucleic acid analyses, multiplex panels, whole genome/exome/transcriptome sequencing, protein expression, and even medical imaging tied to biospecimens). That language gives the Secretary discretion to add technologies that produce comparable results to a named genomic sequencing blood test.
The effective coverage date for any qualifying test is January 1, 2028.The payment change simply inserts these defined screening tests into the Medicare payment provision (section 1833(h)(1)(A)). The bill does not set payment rates, benefit limits, clinical criteria for who should be screened, or require follow-up services.
Implementation will therefore fall to CMS to determine coding, coverage scope (for example, whether screening is population-wide or targeted), clinical guidelines, and how payment is structured under existing laboratory and diagnostic payment systems.Because the text ties coverage to FDA status and leaves the technology scope intentionally broad, the law would make Medicare payers responsible for integrating rapidly evolving diagnostics into the program. That raises practical questions—how CMS will evaluate clinical validity and utility for asymptomatic screening, how it will prevent inappropriate use, and how Medicare will absorb the downstream costs that follow screening (specialist visits, confirmatory testing, counseling, and potential treatment).
The bill creates statutory coverage but leaves operational decisions to CMS.
The Five Things You Need to Know
The bill creates a new statutory definition—section 1861(nnn)—for ‘‘Alzheimer’s disease and related dementias early detection screening tests’’ that takes effect for tests furnished on or after January 1, 2028.
Covered tests must be cleared under FDA section 510(k), classified under 513(f)(2), or approved under 515—the bill ties Medicare eligibility to these specific FDA regulatory pathways.
The statute explicitly lists a genomic sequencing blood or blood product test as a covered test and allows the Secretary to designate ‘‘equivalent’’ technologies, including single-analyte tests, cell-free nucleic acid analysis, multiplex panels, WGS/WES/whole transcriptome, protein expression, and biospecimen-based medical imaging.
The bill amends section 1833(h)(1)(A) of the Social Security Act to add these tests into Medicare’s payment authority, making them payable under Medicare law without specifying rates or billing codes.
The definition covers tests used to detect the pre-symptomatic and early-stage disease, not just symptomatic diagnostics, which raises distinct clinical validity and utility questions for screening asymptomatic beneficiaries.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'ASAP Act'
This brief provision assigns the bill the short title ‘‘Alzheimer’s Screening and Prevention Act’’ (ASAP Act). It has no substantive effect on benefits or implementation but is the statutory handle used in drafting and future references.
Adds Alzheimer’s screening to the list of defined covered tests
The bill inserts a new subparagraph (KK) into 1861(s)(2) to place ‘‘Alzheimer’s disease and related dementias early detection screening tests’’ among Medicare’s defined covered items. That change signals Congress’s intent that these tests belong in the universe of items Medicare may cover and pay for, which triggers downstream administrative processes for coding and coverage determinations.
Defines eligible tests and the FDA/regulatory gate
Subsection (nnn) defines the covered screening test class. It requires that a qualifying test be cleared, classified, or approved through specified FDA authorities (510(k), 513(f)(2), or 515) and then lists technologies that qualify, specifically naming genomic sequencing of blood or blood products and including a broad, catch‑all category for ‘‘equivalent’’ tests. Practically, this ties Medicare access to an FDA regulatory result and gives the Secretary latitude to add comparable technologies without further statutory amendments. That mechanism both constrains coverage to regulated products and broadens the set of technologies that could be reimbursed as science evolves.
Makes the defined screening tests payable under Medicare
The bill inserts the new class of Alzheimer’s screening tests into the Medicare payment provision, meaning CMS must allow payment for tests meeting the statutory definition. The text does not set payment rates, specify the payment system (clinical laboratory fee schedule, physician fee schedule, or other), or define beneficiary eligibility rules; instead, operational details remain with CMS and Medicare contractors to implement under existing payment authorities and administrative processes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries at risk for Alzheimer’s and related dementias — they gain statutory access to FDA-cleared blood-based screening tests for pre-symptomatic and early-stage detection, which could enable earlier diagnosis and care planning.
- Diagnostic test manufacturers and biotech companies — the statutory guarantee of Medicare coverage for qualifying tests creates a large, stable payer market that reduces commercial reimbursement uncertainty and may accelerate investment and commercialization.
- Clinical laboratories and pathology services — labs performing genomic and biomarker analyses will see new demand and potential revenue streams from Medicare-paid screening services.
- Neurology, geriatrics, and primary care practices — clinicians will have reimbursed screening tools to incorporate into risk assessment and early-detection workflows, potentially shifting clinical pathways toward earlier specialty referrals.
Who Bears the Cost
- The Medicare program and taxpayers — expanded coverage for screening, and its downstream consequences (confirmatory diagnostics, specialist care, longitudinal monitoring), will likely increase program spending without statutory limits or offsetting provisions.
- CMS and Medicare administrative contractors — they will need to develop coverage rules, coding, payment rates, and monitoring systems for a new, technically complex benefit with rapidly changing technologies.
- Payers and providers managing incidental findings and follow-up care — health systems may absorb the operational and clinical costs of counseling, confirmatory testing, and care coordination stemming from screening results.
- Manufacturers of tests that are not FDA-cleared or that fail to demonstrate clinical utility — these developers face market exclusion unless they achieve one of the specified FDA regulatory pathways or secure Secretary designation as an equivalent test.
Key Issues
The Core Tension
The bill’s central dilemma is between expanding access to promising diagnostic innovation and protecting Medicare beneficiaries and the program from the medical, fiscal, and ethical harms of premature, broad screening: Congress makes tests payable to encourage detection and innovation, but it does not require or define the clinical evidence or program safeguards that would ensure screening improves outcomes rather than simply increasing costs and harms.
The bill resolves the single statutory barrier to Medicare payment for blood-based dementia screening tests but leaves many consequential questions open. It ties coverage to FDA regulatory status, which provides a clear gate for market entry, yet the enumerated technologies plus the Secretary’s authority to deem ‘‘equivalent’’ tests create a wide door for future assays and analytic platforms.
That combination may foster innovation but also creates regulatory and administrative ambiguity: CMS will have to decide what ‘‘comparable results’’ means in practice and how to audit or revoke coverage if a test’s clinical performance is inadequate.
The statute covers screening for pre-symptomatic and early-stage disease, but it does not set clinical criteria for who should be screened nor require evidence of downstream clinical benefit. Early detection may help planning and access to interventions for some patients, but it also risks false positives, overdiagnosis, psychological harm, and increased spending on confirmatory testing and specialty care.
The bill also does not address privacy and genetic-data protections for genomic sequencing tests tied to Medicare coverage, nor does it create billing or coding rules—these operational responsibilities fall to CMS and could be contentious and time-consuming to implement.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.